CAMBRIDGE, Mass., Oct. 11, 2007 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it has treated the first patient in a multicenter Phase 2 study of the intravenous formulation of M118, the Company’s rationally engineered anticoagulant. The Phase 2 study is designed to treat patients with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). The Company also announced top-line results from a Phase 1 study in healthy volunteers designed to evaluate the human safety and pharmacokinetics of intravenously administered M118. The Company plans to present the complete Phase 1 data at a future medical or scientific forum.
